REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
REVLIMID MAINTENANCE POST AUTO-HSCT
One capsule daily. On Days 1-28 of repeated 28-day cycles.
Start treatment at hematologic recovery and continue until disease progression or unacceptable toxicity.

MAINTENANCE STARTING DOSE
10 mg on Days 1-28
of repeated 28-day cycles
Capsule shown not actual size.
If tolerated, dose can be increased to 15 mg after 3 cycles
Starting dose adjustments for renal impairment:
- 5 mg once daily (CrCl 30–60 mL/min)
- 2.5 mg once daily (CrCl <30 mL/min, not requiring or requiring dialysis*)
*On dialysis days, administer the dose following dialysis.
REVLIMID Dose Modifications Based on Renal Clearance In Patients With MM Post Auto-HSCT

CrCl calculated based on Cockcroft-Gault equations. Capsules shown are not actual size.
Dosing for Patients
with Renal Impairment
See recommendations for renally impaired patients, including patients on dialysis.
DownloadDose Modifications
for Adverse Events
See downloadable dose modifications for select adverse events.
Learn MoreImportant Dosing Information
- The capsules should not be opened, broken, or chewed
- REVLIMID is primarily excreted unchanged by the kidney. Since elderly patients are more likely to have decreased renal function, care should be taken in dose selection. Monitor renal function
- Monitor CBCs every 7 days (weekly) for the first 2 cycles, on Days 1 and 15 of Cycle 3, and every 28 days (4 weeks) thereafter
- Treatment is continued or modified based on clinical and laboratory findings
- Dose modification guidelines are recommended to manage Grade 3/4 neutropenia or thrombocytopenia. For other Grade 3/4 toxicities judged to be related to lenalidomide hold treatment and restart at next lower dose level when toxicity has resolved to ≤Grade 2
- Patients may require dose interruption and/or reduction
- Patients may require the use of blood product support and/or growth factors
Help patients stay on REVLIMID Maintenance with dose modifications.†
†Until disease progression or unacceptable toxicity.
GRADE 3/4 HEMATOLOGIC TOXICITIES

aHematologic recovery: ANC >1000/mcL and/or platelet counts >75,000/mcL.
bDo not dose below 5 mg daily for Days 1-21 of 28-day cycles.
For other Grade 3/4 AEs, hold treatment and after resolution to <Grade 2, restart at next lowest dose.
AE, adverse event; ANC, absolute neutrophil count; CBC, complete blood count; CrCl, creatinine clearance.
Reference: REVLIMID [package insert]. Summit, NJ: Celgene Corp; 2019.